These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21355836)

  • 1. MicroRNAs: a novel therapeutic target for schizophrenia.
    Bravo JA; Dinan TG
    Curr Pharm Des; 2011; 17(2):176-88. PubMed ID: 21355836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs as a target for novel antipsychotics: a systematic review of an emerging field.
    Dinan TG
    Int J Neuropsychopharmacol; 2010 Apr; 13(3):395-404. PubMed ID: 19849891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of miRNA and its potential therapeutic application in schizophrenia.
    Cao T; Zhen XC
    CNS Neurosci Ther; 2018 Jul; 24(7):586-597. PubMed ID: 29529357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Promise of Predictive Biomarkers for Antipsychotic Efficacy: A Review of Peripheral microRNAs to Evaluate Schizophrenia Treatment Response.
    Vadukapuram R; Trivedi C; Shah K; Mansuri Z; Reddy A
    Prim Care Companion CNS Disord; 2022 Apr; 24(2):. PubMed ID: 35395147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment.
    Song HT; Sun XY; Zhang L; Zhao L; Guo ZM; Fan HM; Zhong AF; Niu W; Dai YH; Zhang LY; Shi Z; Liu XP; Lu J
    J Psychiatr Res; 2014 Jul; 54():134-40. PubMed ID: 24694668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA and Posttranscriptional Dysregulation in Psychiatry.
    Geaghan M; Cairns MJ
    Biol Psychiatry; 2015 Aug; 78(4):231-9. PubMed ID: 25636176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs as Therapeutic Targets for Alzheimer's Disease.
    Di Meco A; Praticò D
    J Alzheimers Dis; 2016 May; 53(2):367-72. PubMed ID: 27163828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preliminary analysis of microRNA-21 expression alteration after antipsychotic treatment in patients with schizophrenia.
    Chen SD; Sun XY; Niu W; Kong LM; He MJ; Fan HM; Li WS; Zhong AF; Zhang LY; Lu J
    Psychiatry Res; 2016 Oct; 244():324-32. PubMed ID: 27512922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ziprasidone: a novel psychotropic with unique properties.
    Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
    Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of genomic variants and gene expression data in schizophrenia suggests the potential need for adjunctive therapeutic interventions for neuropsychiatric disorders.
    Anirudh Chellappa S; Pathak AK; Sinha P; Jainarayanan AK; Jain S; Brahmachari SK
    J Genet; 2019 Jun; 98(2):. PubMed ID: 31204709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA dysregulation in psychiatric disease.
    Miller BH; Wahlestedt C
    Brain Res; 2010 Jun; 1338():89-99. PubMed ID: 20303342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on the epigenetics of psychotic diseases and autism.
    Abdolmaleky HM; Zhou JR; Thiagalingam S
    Epigenomics; 2015; 7(3):427-49. PubMed ID: 26077430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.
    de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF
    Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All Roads Lead to the miRNome: miRNAs Have a Central Role in the Molecular Pathophysiology of Psychiatric Disorders.
    O'Connor RM; Gururajan A; Dinan TG; Kenny PJ; Cryan JF
    Trends Pharmacol Sci; 2016 Dec; 37(12):1029-1044. PubMed ID: 27832923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dysregulation of microRNAs and the Role of Stress in the Pathogenesis of Mental Disorders.
    Ivanova E; Bozhilova R; Kaneva R; Milanova V
    Curr Top Med Chem; 2018; 18(21):1893-1907. PubMed ID: 30499408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMDA pathology and treatment of schizophrenia.
    Chang HJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5118-26. PubMed ID: 24410561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.